Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis

Shi,Can; Zhang,Zhenyu

doi:10.3892/ol.2017.6183

Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis

Authors:
- Can Shi
- Zhenyu Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China
Published online on: May 17, 2017 https://doi.org/10.3892/ol.2017.6183
Pages: 725-732
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to screen potential genes implicated in epithelial ovarian cancer (EOC) and to further understand the molecular pathogenesis of EOC. In order to do this, datasets GSE14407 (containing 12 human ovarian cancer epithelia samples and 12 normal epithelia samples) and GSE29220 (containing 11 salivary transcriptomes from ovarian cancer patients with serous papillary adenocarcinoma and 11 matched controls) were obtained from the Gene Expression Omnibus. Differentially expressed genes (DEGs) within these datasets were screened using the Linear Models for Microarray Data package, and potential gene functions were predicted by functional and pathway enrichment analyses. Additionally, module analysis of protein‑protein interaction networks was performed using MCODE software in Cytoscape. The potential microRNAs (miRNAs/miRs) and transcription factors (TFs) regulating DEGs were also analyzed, and the integrated TF‑DEG and miRNA‑DEG regulatory networks were visualized with Cytoscape. In total, 31 upregulated DEGs and 64 downregulated DEGs were screened. The upregulated DEGs, such as centromere protein F (CENPF) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were significantly associated with the cell cycle and were regulated by the TF nuclear transcription factor Y (NF‑Y). CENPF was modulated by miR‑373, and UHRF1 was regulated by miR‑146a. The downregulated DEGs, such as aldehyde dehydrogenase 1 family member A2 (ALDH1A2), were distinctly involved in the response to estrogen stimulus and modulated by tumor protein 53 (TP53); protocadherin 9 (PCDH9) was regulated by TP53, miR‑92b‑3p and miR‑137. The DEGs, including CENPF, UHRF1, ALDH1A2 and PCDH9, and a set of gene regulators, including all NFY genes, TP53, miR‑373, miR‑146a, miR‑92b‑3p and miR‑137, may be involved in the pathogenesis of EOC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S and Pignata S: First-line treatment of advanced ovarian cancer: Current research and perspectives. Expert Rev Anticancer Ther. 10:47–60. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sansone P and Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
4	Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 100:134–144. 2009. View Article : Google Scholar : PubMed/NCBI
5	Mayr D, Hirschmann A, Löhrs U and Diebold J: KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol. 103:883–887. 2006. View Article : Google Scholar : PubMed/NCBI
6	Hennessy B, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD II, Abkevich V, Potter J, Pruss D, Glenn P, et al: Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 28:3570–3576. 2010. View Article : Google Scholar : PubMed/NCBI
7	Peng DX, Luo M, Qiu LW, He YL and Wang XF: Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 27:1238–1244. 2012.PubMed/NCBI
8	Nakano H, Yamada Y, Miyazawa T and Yoshida T: Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol. 42:1875–1882. 2013.PubMed/NCBI
9	Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
10	Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
11	Lee YH, Kim JH, Zhou H, Kim BW and Wong DT: Salivary transcriptomic biomarkers for detection of ovarian cancer: For serous papillary adenocarcinoma. J Mol Med (Berl). 90:427–434. 2012. View Article : Google Scholar : PubMed/NCBI
12	Johnson WE, Li C and Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8:118–127. 2007. View Article : Google Scholar : PubMed/NCBI
13	Leek JT and Storey JD: A general framework for multiple testing dependence. Proc Natl Acad Sci USA. 105:pp. 18718–18723. 2008; View Article : Google Scholar : PubMed/NCBI
14	Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
15	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article32004. View Article : Google Scholar : PubMed/NCBI
16	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Statist Society Series B Methodol. 57:289–300. 1995.
17	Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
18	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
19	von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003. View Article : Google Scholar : PubMed/NCBI
20	Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networksData Mining in Proteomics. Springer; pp. 291–303. 2011
21	He X and Zhang J: Why do hubs tend to be essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI
22	Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
23	Merico D, Isserlin R, Stueker O, Emili A and Bader GD: Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS One. 5:e139842010. View Article : Google Scholar : PubMed/NCBI
24	Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D and Kent WJ: The UCSC table browser data retrieval tool. Nucleic Acids Res. 32:D493–D496. 2004. View Article : Google Scholar : PubMed/NCBI
25	Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P and Hatzigeorgiou AG: The database of experimentally supported targets: A functional update of TarBase. Nucleic Acids Res. 37:D155–D158. 2009. View Article : Google Scholar : PubMed/NCBI
26	Garcia DM, Baek D, Shin C, Bell GW, Grimson A and Bartel DP: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T: miRecords: An integrated resource for microRNA-target interactions. Nucleic Acids Res. 37:D105–D110. 2009. View Article : Google Scholar : PubMed/NCBI
28	Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, et al: The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 38:674–681. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yuen KW, Montpetit B and Hieter P: The kinetochore and cancer: What's the connection? Curr Opin Cell Biol. 17:576–582. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ghosh-Choudhury T, Loomans HA, Wan YW, Liu Z, Hawkins SM and Anderson ML: Abstract 3113: Hyperactivation of FOXM1 drives ovarian cancer growth and metastasis independent of the G2-M cell cycle checkpoint. Cancer Res. 73 Suppl:S31132013. View Article : Google Scholar
31	Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I and Bachvarov D: Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 5:438–453. 2011. View Article : Google Scholar : PubMed/NCBI
32	Lee YC, Huang CC, Lin DY, Chang WC and Lee KH: Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance. PeerJ. 3:e13862015. View Article : Google Scholar : PubMed/NCBI
33	Unoki M, Brunet J and Mousli M: Drug discovery targeting epigenetic codes: The great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol. 78:1279–1288. 2009. View Article : Google Scholar : PubMed/NCBI
34	Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J, Franci C, Huang B, Huang J, Yam GC, et al: Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell. 16:5621–5629. 2005. View Article : Google Scholar : PubMed/NCBI
35	Yan F, Wang X, Shao L, Ge M and Hu X: Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth. Tumor Biol. 36:8887–8893. 2015. View Article : Google Scholar
36	Mantovani R: The molecular biology of the CCAAT-binding factor NF-Y. Gene. 239:15–27. 1999. View Article : Google Scholar : PubMed/NCBI
37	Gurtner A, Fuschi P, Magi F, Colussi C, Gaetano C, Dobbelstein M, Sacchi A and Piaggio G: NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS One. 3:e20472008. View Article : Google Scholar : PubMed/NCBI
38	Yamanaka K, Mizuarai S, Eguchi T, Itadani H, Hirai H and Kotani H: Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics. 94:219–227. 2009. View Article : Google Scholar : PubMed/NCBI
39	Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S and Zhang R: NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res. 11:360–369. 2013. View Article : Google Scholar : PubMed/NCBI
40	Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL and Zhang S: MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget. 5:12291–12303. 2014. View Article : Google Scholar : PubMed/NCBI
41	Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB and Zhao H: A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 29:1963–1966. 2008. View Article : Google Scholar : PubMed/NCBI
42	Mullany LK, Liu Z, King ER, Wong KK and Richards JS: Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology. 153:1638–1648. 2012. View Article : Google Scholar : PubMed/NCBI
43	Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG and Gershenson DM: Significantly greater expression of ER PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 26:404–409. 2007. View Article : Google Scholar : PubMed/NCBI
44	Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC and Gershenson DM: Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 130:565–569. 2013. View Article : Google Scholar : PubMed/NCBI
45	Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM and Smith C: Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. 96:pp. 9118–9123. 1999; View Article : Google Scholar : PubMed/NCBI
46	Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, Wei L and Lichtenegger W: Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med (Berl). 83:457–467. 2005. View Article : Google Scholar : PubMed/NCBI
47	Halon A, Materna V, Drag-Zalesinska M, Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M, Dietel M, Lage H and Surowiak P: Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res. 17:511–518. 2011. View Article : Google Scholar : PubMed/NCBI
48	Liu Q, Chen Y, Pan JJ and Murakami T: Expression of protocadherin-9 and protocadherin-17 in the nervous system of the embryonic zebrafish. Gene Expr Patterns. 9:490–496. 2009. View Article : Google Scholar : PubMed/NCBI
49	Brasch J, Harrison OJ, Honig B and Shapiro L: Thinking outside the cell: How cadherins drive adhesion. Trends Cell Biol. 22:299–310. 2012. View Article : Google Scholar : PubMed/NCBI
50	Bendas G and Borsig L: Cancer cell adhesion and metastasis: Selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012:6767312012. View Article : Google Scholar : PubMed/NCBI
51	Asad M, Wong MK, Tan TZ, Choolani M, Low J, Mori S, Virshup D, Thiery JP and Huang RY: FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell Death Dis. 5:e13462014. View Article : Google Scholar : PubMed/NCBI
52	Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
53	Li Y, Yao L, Liu F, Hong J, Chen L, Zhang B and Zhang W: Characterization of microRNA expression in serous ovarian carcinoma. Int J Mol Med. 34:491–498. 2014.PubMed/NCBI